Back to results
US 2010/0143244 A1Published application
Monoclonal antibodies to human thymidine kinase to treat cancer
AssigneeSavoy Pharmaceuticals, Inc.
InventorNathaniel C. Lallatin
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeSavoy Pharmaceuticals, Inc.
InventorNathaniel C. Lallatin
Estimating the term…
A method of treatment of cancer, viral infections, and the like administers anti-TK1 antibody, constituted as the complete antibody or a fragment thereof. The antibody binds to the surface of cells expressing TK1 thereon. The antibody, with or without another agent bound thereto, may effect complement mediated lysis, antibody-dependent cell-mediated cell cytotoxicity, apoptosis, an immune response by the mammal, a reduction in cellular replication, a combination thereof, or the like for such cells. The antibody may be coupled to an immune response stimulator, a cytotoxin, an enzyme, a combination, or the like to effect the treatment desired.
A method of treatment comprising:
A method for treating cancer characterized by increased expression of TK1 by cancer cells in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising at least one of an anti-TK1 antibody and a fragment of the anti-TK1 antibody selected to be effective to do at least one of inhibit cellular replication of cancer cells and kill cancer cells.
The method of claim 8, wherein the anti-TK1 monoclonal antibody is the Abnova H00007083-M02 antibody.
A method of determining location and spread of neoplastic tissue in a patient comprising:
Dependencies are inferred from the claim text.